novel MSC therapy
progression of DKD
generation MSC therapy
Stabilising progressive DKD
stabilization of progressive DKD
novel MSC population
single dose of MSC
clinical trial
Novel Stromal Cell Therapy
Diabetic Kidney Disease Type
common cause of chronic kidney disease
end-stage renal failure risk
kidney function
trials of ORBCEL
conventional plastic-adherent MSC
NEPHSTROM Phase
superior clinical outcomes
chronic non-communicable disease
placebo
diabetes
adults
preliminary research
NEPHSTROM investigators
single intravenous infusion of allogeneic ORBCEL
Mesenchymal Stromal Cell
high all-cause mortality
preliminary efficacy
adverse outcomes
increased mortality
enormous socioeconomic costs
long-term socioeconomic benefit
optimal design of subsequent Phase
people
mechanisms of action
immunological effects
CD362
NEPHSTROMâ€™s
improved characterisation
economic impacts
glomerular filtration rate
albuminuria
secondary complications
transplantation
mainstay treatments
tolerability
safety
bio-distribution
multi-centre
promising approach
dialysis
higher purity
limited protection
trade
hyperglycaemia
key enabler
Pharmacotherapy
benefits
animals
ancillary